OBJECTIVES Advanced glycation end products, along with methylglyoxal (MGO) as their precursor, play a major role in increased complications of type 2 diabetes mellitus (T2DM). Taurine (2-aminoethanesulphonic acid), a conditionally essential amino acid, is found in most mammalian tissues. Taurine is known as an antiglycation compound. This study was designed to investigate the effects of taurine supplementation on metabolic profiles, pentosidine, MGO and soluble receptors for advanced glycation end products in patients with T2DM. METHODS In this double-blind randomized controlled trial, 46 patients with T2DM were randomly allocated into taurine and placebo groups. Participants received either 3,000 mg/day taurine or placebo for 8 weeks. Metabolic profiles, pentosidine, MGO and soluble receptors for advanced glycation end products levels were assessed after 12 h of fasting at baseline and completion of the clinical trial. Independent t test, paired t test, Pearson correlation and analysis of covariance were used for analysis. RESULTS The mean serum levels of fasting blood sugar (p=0.01), glycated hemoglobin (p=0.04), insulin (p=0.03), homeostasis model assessment-insulin resistance (p=0.004), total cholesterol (p=0.01) and low-density lipoprotein cholesterol (p=0.03) significantly were reduced in the taurine group at completion compared with the placebo group. In addition, after completion of the study, pentosidine (p=0.004) and MGO (p=0.006) were significantly reduced in the taurine group compared with the placebo group. CONCLUSIONS The results of this trial show that taurine supplementation may decrease diabetes complications through improving glycemic control and advanced glycation end products.

中文翻译：

---

牛磺酸补充剂对 2 型糖尿病患者代谢特征、戊糖苷、晚期糖基化终产物的可溶性受体和甲基乙二醛的影响：一项随机、双盲、安慰剂对照试验

目标 晚期糖基化终产物，连同作为其前体的甲基乙二醛 (MGO)，在 2 型糖尿病 (T2DM) 并发症增加中起主要作用。牛磺酸（2-氨基乙磺酸）是一种条件必需氨基酸，存在于大多数哺乳动物组织中。牛磺酸被称为抗糖化化合物。本研究旨在研究牛磺酸补充剂对 T2DM 患者代谢特征、戊糖苷、MGO 和晚期糖基化终产物的可溶性受体的影响。方法 在这项双盲随机对照试验中，46 名 T2DM 患者被随机分配到牛磺酸组和安慰剂组。参与者接受了 3,000 毫克/天的牛磺酸或安慰剂，为期 8 周。代谢谱，戊糖素，在基线禁食 12 小时和临床试验完成后，评估 MGO 和晚期糖基化终产物水平的可溶性受体。采用独立t检验、配对t检验、Pearson相关和协方差分析进行分析。结果空腹血糖（p=0.01）、糖化血红蛋白（p=0.04）、胰岛素（p=0.03）、稳态模型评估-胰岛素抵抗（p=0.004）、总胆固醇（p=0.01）和与安慰剂组相比，牛磺酸组在完成时的低密度脂蛋白胆固醇 (p=0.03) 显着降低。此外，在完成研究后，与安慰剂组相比，牛磺酸组的戊糖苷 (p=0.004) 和 MGO (p=0.006) 显着减少。